Inotiv Inc (NOTV) FinancialsNOTVInotiv Inc

Inotiv Inc (NOTV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is RMS, accounting for 60.0% of total sales, equivalent to $70.57M. Another important revenue stream is DSA. Understanding this composition is critical for investors evaluating how NOTV navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Inotiv Inc maintains a gross margin of 8.98%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13.91%, while the net margin is -27.60%. These profitability ratios, combined with a Return on Equity (ROE) of -74.09%, provide a clear picture of how effectively NOTV converts its operational activities into shareholder value.

In the context of the broader market, NOTV competes directly with industry leaders such as XHLD and MLEC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NOTV's gross margin of 8.98% stands against XHLD's 70.04% and MLEC's -25.78%. Such benchmarking helps identify whether Inotiv Inc is trading at a premium or discount relative to its financial performance.